Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
  • CME
  • CE

Credits Available
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 14, 2020 Expiration: October 13, 2021
Start Activity
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed chronic lymphocytic leukemia
  • Evaluate promising investigational agents and novel combination regimens in chronic lymphocytic leukemia, including efficacy, unique toxicities, and other practical management considerations
  • Describe the role of measurable residual disease assessment in chronic lymphocytic leukemia care

Information on this Educational Activity

Program Director

Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from Acerta, AbbVie, Astra Zeneca, BeiGene, Janssen, Pharmacyclics, Genentech, Pfizer, and TG Therapeutics.

Faculty

Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has served on advisory boards for AbbVie, BeiGene, Celgene, Kite, and Novartis, and received consulting fees from AstraZeneca, Incyte, and Morphosys.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

USF Health OCPD staff have no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with chronic lymphocytic leukemia.

Goal

The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with chronic lymphocytic leukemia.

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.25 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

Pharmacist Continuing Education

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.25 contact hours (0.025 CEU). Universal program number is as follows: 0230-9999-20-031-H01-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate.

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 14, 2020, through October 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
  • CME
  • CE

In this installment of CCO’s concise patient case series, Jeremy S. Abramson, MD, MMSc, discusses treatment considerations for a patient with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.
Jeff P. Sharman, MD
Program Director
Jeremy S. Abramson, MD, MMSc
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: October 14, 2020 Expiration: October 13, 2021

Related Content

Preview expert ITP abstract selections from ASH 2020 as part of conference coverage from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: November 24, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

Expert commentary from Clinical Care Options (CCO) on challenges in diagnosing and treating patients with myelodysplastic syndromes (MDS)

Rami S. Komrokji, MD Released: November 20, 2020

Enter the characteristics of your patient with CLL into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Jeff P. Sharman, MD
Program Director
Released: November 20, 2020
Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue